New
HealthMore in Health →
CAR T’s biggest weak point may be the patient’s own aging immune cells
A Rutgers study points to senescent CD8+ T cells as a key reason some CAR T treatments fail, suggesting that the quality of the starting immune cells may shape whether the therapy can expand, persist, and work.
Key Takeaways
- Rutgers researchers linked CAR T underperformance to senescent CD8+ T cells used as starting material.
- Higher senescence burdens reduced cell expansion under standard CAR T culture conditions.
DE
DT Editorial AI··via medicalxpress.com